Table 1.
Patients and Tumors Characteristics
| Variables | N = 41* | ||
|---|---|---|---|
| Gender | Male | 25 | 61% |
| Age | 64* | (25–89)* | |
| Body mass index | 25* | (16–38)* | |
| Karnofsky Performance Status | pre-COVID19 (%) | 60 | (40–100) |
| Undetermined | 2 | 5% | |
| <60 | 15 | 37% | |
| 60–80 | 16 | 39% | |
| >80 | 8 | 20% | |
| Type of glioma | Glioblastoma (IDHmt) | 32 | 78% |
| Grade III Astrocytoma | 6 | 15% | |
| Grade III Oligodendroglioma | 2 | 5% | |
| Grade II Oligodendroglioma | 1 | 2% | |
| Comorbidities | Diabetes mellitus | 5 | 12% |
| Hypertension | 9 | 22% | |
| Cancer (excluding glioma) | 9 | 22% | |
| Rheumatologic | 5 | 12% | |
| Cardiac disease | 4 | 10% | |
| Metabolic | 5 | 12% | |
| Vascular | 5 | 12% | |
| Endocrinologic disease (excluding diabetes) | 4 | 10% | |
| Neurologic disease (excluding glioma) | 3 | 7% | |
| Hepatic | 2 | 5% | |
| Lung | 3 | 7% | |
| Digestive | 2 | 5% | |
| Chronic kidney failure | 2 | 5% | |
| Positive RT-PCR | 38 | 93% | |
| Positive Chest CT scan | 18 | 44% | |
| Serology positive | 6 | 15% | |
| Steroid Treatment | 31 | 76% | |
| Oncological treatment within 1 month prior to COVID-19 | Surgery | 1 | 2% |
| Chemotherapy | 24 | 59% | |
| Radiotherapy | 3 | 7% | |
| Status of tumor | Stable disease | 14 | 34% |
| Complete response | 0 | 0% | |
| Partial response | 3 | 7% | |
| Progressive disease | 18 | 44% | |
| Not specified | 6 | 15% | |
| Line of treatment | Newly diagnosed/First | 22 | 54% |
| Second | 12 | 29% | |
| Third | 4 | 10% | |
| Remission | 2 | 5% | |
| Palliative care | 1 | 2% | |
| In-patient care | 33 | 81% | |
| Impact of COVID-19 on oncological treatment | Oncological treatment delayed | 21 | 51% |
| Oncological treatment not delayed | 7 | 17% | |
| Patients monitored without oncological treatment | 13 | 32% |
*Data are presented as n (%), median, IQR as appropriate.